BeOne Medicines Ltd. (ONC)
Nasdaq: ONC · Pharmaceutical Preparations · Basel · filing with the SEC since 2015
Who owns BeOne Medicines Ltd.
As filed with the SECHolders of 5% or more
1
Baker Bros. Advisors LP holds 7.8% of Ordinary Shares, par value $0.0001 per share, as its SCHEDULE 13D/A filed Sep 16, 2026 says.
Directors and officers
22
report now, of 38 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Baker Bros. Advisors LP
SCHEDULE 13D/A · filed Sep 16, 2026 · Ordinary Shares, par value $0.0001 per share · 8% in Jun 15, 2026
HHLR Advisors, Ltd.
SCHEDULE 13D/A · filed May 13, 2025 · Ordinary shares, par value $0.0001 per share · reported falling below 5%, from 6.7% in Mar 3, 2025
Capital International Investors
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock · reported falling below 5%, from 5.8% in May 13, 2025
What ONC reports owning in othersstakes of 5% or more, and other ties
Cypherpunk Technologies Inc. CYPH
SCHEDULE 13D/A · filed Oct 31, 2024 · Common Stock, par value $0.001 per share · reported falling below 5%
62 subsidiaries in 36 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
209sales
0purchases
158sales on a scheduled plan
12people selling
$389Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 48 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Oyler John | Chief Executive Officer | 121 | $328M | 109 | 0 | $0 |
| Wang Xiaodong | director | 34 | $46.8M | 34 | 0 | $0 |
| Wu Xiaobin | President and COO | 19 | $8.8M | 1 | 0 | $0 |
| Lee Chan Henry | SVP, General Counsel | 21 | $5.1M | 16 | 0 | $0 |
| Wang Lai | President, Global Head of R&D | 5 | $1.2M | 0 | 0 | $0 |
| Sanders Corazon (Corsee) D. | director | 3 | $1.0M | 0 | 0 | $0 |
| Ball Titus B. | Principal Accounting Officer | 7 | $800,000 | 0 | 0 | $0 |
| Rosenberg Aaron | Chief Financial Officer | 2 | $500,000 | 0 | 0 | $0 |
| Baker Bros. Advisors LP | director | 4 | $300,000 | 0 | 0 | $0 |
| Dugan Margaret | director | 1 | $100,000 | 0 | 0 | $0 |
| Riva Alessandro | director | 1 | $100,000 | 0 | 0 | $0 |
| Yi Qingqing | director | 1 | $100,000 | 0 | 0 | $0 |